Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development
TipRanksMar 25 06:46 ET
Armata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Losses
Yahoo FinanceMar 23 05:33 ET
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
TipRanksMar 23 02:00 ET
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 22 11:09 ET
Express News | HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Moomoo 24/7Mar 22 10:58 ET
Armata Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 101.15% HC Wainwright & Co. $7 → $7 Maintains Buy 08/14/2023 101.15% HC Wainwright & Co. $7 → $
BenzingaMar 22 10:57 ET
Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth
TipRanksMar 22 06:17 ET
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
04:09 PM EDT, 03/21/2024 (MT Newswires) -- Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
MT NewswiresMar 21 16:09 ET
Armata Pharmaceuticals Q4 EPS $(0.55) Misses $(0.35) Estimate, Sales $1.53M Beat $860.00K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 89.66 percent decrease over losses
BenzingaMar 21 16:07 ET
Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP
Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP
Dow JonesMar 21 16:05 ET
Press Release: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES, March 21, 2024 LOS ANGELES, March 21, 2024 /PRNewswire/ -- Armata P
Dow JonesMar 21 16:05 ET
Express News | Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva
Moomoo 24/7Mar 4 16:03 ET
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
LOS ANGELES, Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut
PR NewswireFeb 21 07:00 ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersSana Biotechnology (NASDAQ:SANA) shares increased by 45.2% to $7.49 during Wednesday's regular session. The company's market cap stands at $1.4 billion. Amarin Corp (NASDAQ:AMRN) stock increase
BenzingaJan 10 12:31 ET
Armata Pharmaceuticals: A Promising Buy Based on Therapeutic Pipeline, Financial Stability, and Strategic Partnerships
TipRanksNov 15, 2023 06:46 ET
Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals' Buy Rating
TipRanksNov 15, 2023 06:22 ET
Armata Pharmaceuticals Q3 EPS $(0.86) Misses $(0.31) Estimate, Sales $1.23M Beat $950.00K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.31) by 177.42 percent. This is a 258.33 percent decrease over losse
BenzingaNov 14, 2023 16:05 ET
Armata Pharmaceuticals 3Q Loss/Shr 86c >ARMP
Armata Pharmaceuticals 3Q Loss/Shr 86c >ARMP
Dow JonesNov 14, 2023 16:00 ET
Express News | Armata Pharmaceuticals Announces Presentation of Topline Data From SWARM-P.a. Clinical Study Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients At North American Cystic Fibrosis Conference
Moomoo 24/7Oct 30, 2023 08:07 ET
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutic
PR NewswireOct 19, 2023 08:00 ET
No Data
No Data